icon-folder.gif   Conference Reports for NATAP  
61th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2010
Back grey_arrow_rt.gif
Three-Day, Dose-Ranging Study Of The HCV NS3 Protease Inhibitor GS-9451
  Reported by Jules Levin
AASLD 2010 Nov 2 Boston
E Lawitz1, J Hill2, T Marbury3, M Rodriguez-Torres4, M DeMicco5, J Quesada6, P Shaw7, S Gordon8, M Shelton9, D Coombs9, J Zong9, A Bae9, K Wong9, H Mo9, E Mondou9, K Hirsch9, W Delaney9 1Alamo Medical Research, San Antonio, TX, 2Avail Clinical Research, Deland, FL, 3Orlando Clinical Research Center, Orlando, FL,4Fundacion De Investigacion De Diego, Santurce, PR, 5Advanced Clinical Research Institute, Anaheim, CA, 6West Coast Clinical Trials, Cypress, CA, 7Charles River, Tacoma, WA, 8Henry Ford Health System, Detroit, MI, 9Gilead Sciences, Inc. Foster City, CA.